Υπνωτικό (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Υπνωτικό" in Greek language version.

refsWebsite

Global rank Greek rank

40nih.gov

4^th place

29doi.org

2^nd place

3^rd place

8archive.org

6^th place

5^th place

4web.archive.org

1^st place

1mercksource.com

8,363^rd place

low place

1nps.org.au

low place

1ic.ac.uk

low place

7,510^th place

1worldcat.org

5^th place

8^th place

1nice.org.uk

3,258^th place

2,509^th place

1aafp.org

1,916^th place

1,112^th place

1books.google.com

3^rd place

6^th place

1choosingwisely.org

7,197^th place

4,616^th place

1medscape.com

719^th place

579^th place

aafp.org

«Treatment options for insomnia». American Family Physician 76 (4): 517–526. August 2007. PMID 17853625. http://www.aafp.org/afp/2007/0815/p517.html.

archive.org

«17: Hypnotics and Sedatives». Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th έκδοση). The McGraw-Hill Companies, Inc. 2006. ISBN 978-0-07-146804-6. Ανακτήθηκε στις 6 Φεβρουαρίου 2014.
«Sleep and hypnotic drugs». Drugs 9 (6): 448–478. 1975. doi:10.2165/00003495-197509060-00004. PMID 238826. https://archive.org/details/sim_drugs_1975_9_6/page/448.
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680.
«GABA and glycine». Basic Neurochemistry: Molecular, Cellular and Medical Aspects (7th έκδοση). Elsevier. 2006. σελίδες 291–302. ISBN 978-0-12-088397-4.
«Diagnosis and treatment of chronic insomnia: a review». Psychiatric Services 56 (3): 332–343. March 2005. doi:10.1176/appi.ps.56.3.332. PMID 15746509. https://archive.org/details/sim_psychiatric-services_2005-03_56_3/page/332. «Evidence for the utility of currently available nonbenzodiazepine hypnotics points to their primary efficacy as sleep-onset, rather than as sleep-maintenance, agents. Once again, longer-term randomized, double-blind, controlled studies that demonstrate efficacy of these agents have not been performed, but safety over the longer term has been demonstrated in open-label studies, with minimal evidence of rebound phenomena. By comparison with benzodiazepines, there has been less evidence of subjective and objective next-day residual effects associated with zolpidem or subjective next-day impairment with zaleplon, even when the latter has been delivered in the middle of the night.».
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680. «New developments in benzodiazepine receptor pharmacology have introduced novel nonbenzodiazepine hypnotics that provide comparable efficacy to benzodiazepines. Although they may possess theoretical advantages over benzodiazepines based on their unique pharmacologic profiles, they offer few, if any, significant advantages in terms of adverse effects.».
«Mirtazapine: a newer antidepressant». American Family Physician 59 (1): 159–161. January 1999. PMID 9917581. https://archive.org/details/sim_american-family-physician_1999-01-01_59_1/page/n162.
«Safety of low doses of quetiapine when used for insomnia». The Annals of Pharmacotherapy 46 (5): 718–722. May 2012. doi:10.1345/aph.1Q697. PMID 22510671. https://archive.org/details/sim_annals-of-pharmacotherapy_2012-05_46_5/page/718.

books.google.com

Handbook of Integrative Clinical Psychology, Psychiatry, and Behavioral Medicine: Perspectives, Practices, and Research. Springer Publishing Company. 13 Δεκεμβρίου 2009. σελίδες 128–30. ISBN 978-0-8261-1094-7.

choosingwisely.org

American Geriatrics Society. «Five Things Physicians and Patients Should Question». Choosing Wisely: an initiative of the ABIM Foundation. American Geriatrics Society. Ανακτήθηκε στις 1 Αυγούστου 2013. , which cites

doi.org

dx.doi.org

«Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010». Pharmacoepidemiology and Drug Safety 25 (6): 637–645. June 2016. doi:10.1002/pds.3951. PMID 26711081.
«Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits». BMJ 331 (7526): 1169. November 2005. doi:10.1136/bmj.38623.768588.47. PMID 16284208.
«What's wrong with prescribing hypnotics?». Drug and Therapeutics Bulletin 42 (12): 89–93. December 2004. doi:10.1136/dtb.2004.421289. PMID 15587763.
«Melatonin as a hypnotic: pro». Sleep Medicine Reviews 9 (1): 51–65. February 2005. doi:10.1016/j.smrv.2004.04.003. PMID 15649738.
«Suicide in Brisbane, 1956 to 1973: the drug-death epidemic». The Medical Journal of Australia 1 (24): 737–743. June 1975. doi:10.5694/j.1326-5377.1975.tb111781.x. PMID 239307.
«Sleep and hypnotic drugs». Drugs 9 (6): 448–478. 1975. doi:10.2165/00003495-197509060-00004. PMID 238826. https://archive.org/details/sim_drugs_1975_9_6/page/448.
«Synthetic Approaches Towards Quinazolines, Quinazolinones and Quinazolinediones on Solid Phase». QSAR & Combinatorial Science 23 (6): 440–459. July 2004. doi:10.1002/qsar.200420018. ISSN 1611-020X.
«Benefit-risk assessment of zaleplon in the treatment of insomnia». Drug Safety 28 (4): 301–318. 2005. doi:10.2165/00002018-200528040-00003. PMID 15783240.
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680.
«How theories evolved concerning the mechanism of action of barbiturates». Epilepsia 53 (Suppl 8): 12–25. December 2012. doi:10.1111/epi.12025. PMID 23205959.
«In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy». Molecular Cancer Therapeutics 5 (12): 3001–3013. December 2006. doi:10.1158/1535-7163.MCT-06-0465. PMID 17172404.
«The diagnosis and management of benzodiazepine dependence». Current Opinion in Psychiatry 18 (3): 249–255. May 2005. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
«Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse». Behaviour Research and Therapy 43 (1): 1–14. January 2005. doi:10.1016/j.brat.2003.12.002. PMID 15531349.
«Chronic benzodiazepine usage and withdrawal in insomnia patients». Journal of Psychiatric Research 38 (3): 327–334. 2004-06-01. doi:10.1016/j.jpsychires.2003.10.003. PMID 15003439.
«Manifestations and management of chronic insomnia in adults». Evidence Report/Technology Assessment (Agency for Healthcare Research and Quality) (125): 1–10. June 2005. doi:10.1037/e439752005-001. PMID 15989374.
«Diagnosis and treatment of chronic insomnia: a review». Psychiatric Services 56 (3): 332–343. March 2005. doi:10.1176/appi.ps.56.3.332. PMID 15746509. https://archive.org/details/sim_psychiatric-services_2005-03_56_3/page/332. «Evidence for the utility of currently available nonbenzodiazepine hypnotics points to their primary efficacy as sleep-onset, rather than as sleep-maintenance, agents. Once again, longer-term randomized, double-blind, controlled studies that demonstrate efficacy of these agents have not been performed, but safety over the longer term has been demonstrated in open-label studies, with minimal evidence of rebound phenomena. By comparison with benzodiazepines, there has been less evidence of subjective and objective next-day residual effects associated with zolpidem or subjective next-day impairment with zaleplon, even when the latter has been delivered in the middle of the night.».
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680. «New developments in benzodiazepine receptor pharmacology have introduced novel nonbenzodiazepine hypnotics that provide comparable efficacy to benzodiazepines. Although they may possess theoretical advantages over benzodiazepines based on their unique pharmacologic profiles, they offer few, if any, significant advantages in terms of adverse effects.».
«Melatonin as a chronobiotic». Sleep Medicine Reviews 9 (1): 25–39. February 2005. doi:10.1016/j.smrv.2004.05.002. PMID 15649736.
«Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders». Drugs & Aging 4 (4): 331–355. April 1994. doi:10.2165/00002512-199404040-00006. PMID 8019056.
«Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study». The Journal of Clinical Psychiatry 62 (6): 453–463. June 2001. doi:10.4088/JCP.v62n0609. PMID 11465523.
«Efficacy and side effects of mianserin, a tetracyclic antidepressant». Postgraduate Medical Journal 59 (690): 229–231. April 1983. doi:10.1136/pgmj.59.690.229. PMID 6346303.
«Insomnia in patients with depression: some pathophysiological and treatment considerations». CNS Drugs 23 (4): 309–329. 2009. doi:10.2165/00023210-200923040-00004. PMID 19374460.
«Safety of low doses of quetiapine when used for insomnia». The Annals of Pharmacotherapy 46 (5): 718–722. May 2012. doi:10.1345/aph.1Q697. PMID 22510671. https://archive.org/details/sim_annals-of-pharmacotherapy_2012-05_46_5/page/718.
«Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study». World Psychiatry 21 (3): 444–451. October 2022. doi:10.1002/wps.21010. PMID 36073694.
«Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis». The Lancet. Psychiatry 7 (1): 64–77. January 2020. doi:10.1016/s2215-0366(19)30416-x. PMID 31860457.
«Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia». Behavioural Brain Research 402: 113098. March 2021. doi:10.1016/j.bbr.2020.113098. PMID 33417992.
«Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis» (στα English). Lancet 400 (10347): 170–184. July 2022. doi:10.1016/S0140-6736(22)00878-9. PMID 35843245.
«Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–962. September 2013. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
«Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis». Lancet 400 (10347): 170–184. July 2022. doi:10.1016/S0140-6736(22)00878-9. PMID 35843245.

ic.ac.uk

ch.ic.ac.uk

«Barbiturates». Αρχειοθετήθηκε από το πρωτότυπο στις 7 Νοεμβρίου 2007. Ανακτήθηκε στις 31 Οκτωβρίου 2007.

medscape.com

reference.medscape.com

«Levate (amitriptyline), dosing, indications, interactions, adverse effects, and more». Medscape Reference. WebMD. Ανακτήθηκε στις 1 Δεκεμβρίου 2013.

mercksource.com

«Dorlands Medical Dictionary:hypnotic». Mercksource.com. Αρχειοθετήθηκε από το πρωτότυπο στις 11 Δεκεμβρίου 2008.

nice.org.uk

«Technology Appraisal Guidance 77. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia» (PDF). National Institute for Clinical Excellence. Απριλίου 2004. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 3 Δεκεμβρίου 2008. Ανακτήθηκε στις 26 Ιουλίου 2009.

nih.gov

ncbi.nlm.nih.gov

«Criteria for selection of appropriate benzodiazepine hypnotic therapy». The Journal of Clinical Psychiatry. 52 52 (Suppl): 42–46. September 1991. PMID 1680126.
«Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010». Pharmacoepidemiology and Drug Safety 25 (6): 637–645. June 2016. doi:10.1002/pds.3951. PMID 26711081.
«Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits». BMJ 331 (7526): 1169. November 2005. doi:10.1136/bmj.38623.768588.47. PMID 16284208.
«What's wrong with prescribing hypnotics?». Drug and Therapeutics Bulletin 42 (12): 89–93. December 2004. doi:10.1136/dtb.2004.421289. PMID 15587763.
«Melatonin as a hypnotic: pro». Sleep Medicine Reviews 9 (1): 51–65. February 2005. doi:10.1016/j.smrv.2004.04.003. PMID 15649738.
«Suicide in Brisbane, 1956 to 1973: the drug-death epidemic». The Medical Journal of Australia 1 (24): 737–743. June 1975. doi:10.5694/j.1326-5377.1975.tb111781.x. PMID 239307.
«Sleep and hypnotic drugs». Drugs 9 (6): 448–478. 1975. doi:10.2165/00003495-197509060-00004. PMID 238826. https://archive.org/details/sim_drugs_1975_9_6/page/448.
«[New hypnotics: perspectives from sleep physiology]». Vertex 18 (74): 294–299. July–August 2007. PMID 18265473.
«Benefit-risk assessment of zaleplon in the treatment of insomnia». Drug Safety 28 (4): 301–318. 2005. doi:10.2165/00002018-200528040-00003. PMID 15783240.
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680.
«How theories evolved concerning the mechanism of action of barbiturates». Epilepsia 53 (Suppl 8): 12–25. December 2012. doi:10.1111/epi.12025. PMID 23205959.
«In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy». Molecular Cancer Therapeutics 5 (12): 3001–3013. December 2006. doi:10.1158/1535-7163.MCT-06-0465. PMID 17172404.
«Treatment options for insomnia». American Family Physician 76 (4): 517–526. August 2007. PMID 17853625. http://www.aafp.org/afp/2007/0815/p517.html.
«The diagnosis and management of benzodiazepine dependence». Current Opinion in Psychiatry 18 (3): 249–255. May 2005. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
«Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse». Behaviour Research and Therapy 43 (1): 1–14. January 2005. doi:10.1016/j.brat.2003.12.002. PMID 15531349.
«Chronic benzodiazepine usage and withdrawal in insomnia patients». Journal of Psychiatric Research 38 (3): 327–334. 2004-06-01. doi:10.1016/j.jpsychires.2003.10.003. PMID 15003439.
«Manifestations and management of chronic insomnia in adults». Evidence Report/Technology Assessment (Agency for Healthcare Research and Quality) (125): 1–10. June 2005. doi:10.1037/e439752005-001. PMID 15989374.
«GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics». The British Journal of General Practice 56 (533): 964–967. December 2006. PMID 17132386.
«Diagnosis and treatment of chronic insomnia: a review». Psychiatric Services 56 (3): 332–343. March 2005. doi:10.1176/appi.ps.56.3.332. PMID 15746509. https://archive.org/details/sim_psychiatric-services_2005-03_56_3/page/332. «Evidence for the utility of currently available nonbenzodiazepine hypnotics points to their primary efficacy as sleep-onset, rather than as sleep-maintenance, agents. Once again, longer-term randomized, double-blind, controlled studies that demonstrate efficacy of these agents have not been performed, but safety over the longer term has been demonstrated in open-label studies, with minimal evidence of rebound phenomena. By comparison with benzodiazepines, there has been less evidence of subjective and objective next-day residual effects associated with zolpidem or subjective next-day impairment with zaleplon, even when the latter has been delivered in the middle of the night.».
«Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia». The Annals of Pharmacotherapy 32 (6): 680–691. June 1998. doi:10.1345/aph.17111. PMID 9640488. https://archive.org/details/sim_annals-of-pharmacotherapy_1998-06_32_6/page/680. «New developments in benzodiazepine receptor pharmacology have introduced novel nonbenzodiazepine hypnotics that provide comparable efficacy to benzodiazepines. Although they may possess theoretical advantages over benzodiazepines based on their unique pharmacologic profiles, they offer few, if any, significant advantages in terms of adverse effects.».
«Melatonin as a chronobiotic». Sleep Medicine Reviews 9 (1): 25–39. February 2005. doi:10.1016/j.smrv.2004.05.002. PMID 15649736.
«Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders». Drugs & Aging 4 (4): 331–355. April 1994. doi:10.2165/00002512-199404040-00006. PMID 8019056.
«Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study». The Journal of Clinical Psychiatry 62 (6): 453–463. June 2001. doi:10.4088/JCP.v62n0609. PMID 11465523.
«Efficacy and side effects of mianserin, a tetracyclic antidepressant». Postgraduate Medical Journal 59 (690): 229–231. April 1983. doi:10.1136/pgmj.59.690.229. PMID 6346303.
«Mirtazapine: a newer antidepressant». American Family Physician 59 (1): 159–161. January 1999. PMID 9917581. https://archive.org/details/sim_american-family-physician_1999-01-01_59_1/page/n162.
«Insomnia in patients with depression: some pathophysiological and treatment considerations». CNS Drugs 23 (4): 309–329. 2009. doi:10.2165/00023210-200923040-00004. PMID 19374460.
«Safety of low doses of quetiapine when used for insomnia». The Annals of Pharmacotherapy 46 (5): 718–722. May 2012. doi:10.1345/aph.1Q697. PMID 22510671. https://archive.org/details/sim_annals-of-pharmacotherapy_2012-05_46_5/page/718.
«Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study». World Psychiatry 21 (3): 444–451. October 2022. doi:10.1002/wps.21010. PMID 36073694.
«Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis». The Lancet. Psychiatry 7 (1): 64–77. January 2020. doi:10.1016/s2215-0366(19)30416-x. PMID 31860457.
«Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia». Behavioural Brain Research 402: 113098. March 2021. doi:10.1016/j.bbr.2020.113098. PMID 33417992.
«Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis» (στα English). Lancet 400 (10347): 170–184. July 2022. doi:10.1016/S0140-6736(22)00878-9. PMID 35843245.
«Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–962. September 2013. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
«Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis». Lancet 400 (10347): 170–184. July 2022. doi:10.1016/S0140-6736(22)00878-9. PMID 35843245.

pubmedcentral.nih.gov

«Trends in prescribing of sedative-hypnotic medications in the USA: 1993-2010». Pharmacoepidemiology and Drug Safety 25 (6): 637–645. June 2016. doi:10.1002/pds.3951. PMID 26711081.
«Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits». BMJ 331 (7526): 1169. November 2005. doi:10.1136/bmj.38623.768588.47. PMID 16284208.
«Manifestations and management of chronic insomnia in adults». Evidence Report/Technology Assessment (Agency for Healthcare Research and Quality) (125): 1–10. June 2005. doi:10.1037/e439752005-001. PMID 15989374.
«GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics». The British Journal of General Practice 56 (533): 964–967. December 2006. PMID 17132386.
«Efficacy and side effects of mianserin, a tetracyclic antidepressant». Postgraduate Medical Journal 59 (690): 229–231. April 1983. doi:10.1136/pgmj.59.690.229. PMID 6346303.
«Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study». World Psychiatry 21 (3): 444–451. October 2022. doi:10.1002/wps.21010. PMID 36073694.
«Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis». The Lancet. Psychiatry 7 (1): 64–77. January 2020. doi:10.1016/s2215-0366(19)30416-x. PMID 31860457.

nps.org.au

National Prescribing Service (2 Φεβρουαρίου 2010). «NPS News 67: Addressing hypnotic medicines use in primary care». Αρχειοθετήθηκε από το πρωτότυπο στις 22 Φεβρουαρίου 2011. Ανακτήθηκε στις 19 Μαρτίου 2010.

web.archive.org

«Dorlands Medical Dictionary:hypnotic». Mercksource.com. Αρχειοθετήθηκε από το πρωτότυπο στις 11 Δεκεμβρίου 2008.
National Prescribing Service (2 Φεβρουαρίου 2010). «NPS News 67: Addressing hypnotic medicines use in primary care». Αρχειοθετήθηκε από το πρωτότυπο στις 22 Φεβρουαρίου 2011. Ανακτήθηκε στις 19 Μαρτίου 2010.
«Barbiturates». Αρχειοθετήθηκε από το πρωτότυπο στις 7 Νοεμβρίου 2007. Ανακτήθηκε στις 31 Οκτωβρίου 2007.
«Technology Appraisal Guidance 77. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia» (PDF). National Institute for Clinical Excellence. Απριλίου 2004. Αρχειοθετήθηκε από το πρωτότυπο (PDF) στις 3 Δεκεμβρίου 2008. Ανακτήθηκε στις 26 Ιουλίου 2009.

worldcat.org

«Synthetic Approaches Towards Quinazolines, Quinazolinones and Quinazolinediones on Solid Phase». QSAR & Combinatorial Science 23 (6): 440–459. July 2004. doi:10.1002/qsar.200420018. ISSN 1611-020X.